Long Term Safety Assessment of SER120 in Patients With Nocturia

NCT00981682 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 376

Last updated 2021-01-20

Study results available
· View outcomes & findings →

Summary

The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.

Conditions

  • Nocturia

Interventions

DRUG

SER120

once a day treatment of nocturia

Sponsors & Collaborators

  • Serenity Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2011-06-30
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00981682 on ClinicalTrials.gov